Tg Therapeutics (TGTX) Change in Accured Expenses (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Change in Accured Expenses of $34.0 million for Q1 2026, down 47.81% year-over-year from $65.2 million in Q1 2025, and up 12687.97% quarter-over-quarter from $266000.0 in Q4 2025.
Tg Therapeutics (TGTX) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Tg Therapeutics' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $34.0 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 47.81% year-over-year to $34.0 million; the TTM figure through Mar 2026 stood at -$33.5 million (down 170.18% YoY), while the FY2025 annual figure was -$2.4 million, down 110.43% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $34.0 million, up from $266000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $65.2 million in Q1 2025, with the low at -$67.5 million in Q2 2025.
- The 5-year median for Change in Accured Expenses is $2.4 million (2022), against an average of $3.5 million.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses tumbled 1905.92% in 2022, then soared 6397.9% in 2024.
- Tg Therapeutics' Change in Accured Expenses stood at $874000.0 in 2022, then soared by 477.46% to $5.0 million in 2023, then jumped by 296.02% to $20.0 million in 2024, then plunged by 98.67% to $266000.0 in 2025, then soared by 12687.97% to $34.0 million in 2026.
- Business Quant data shows TGTX's Change in Accured Expenses at $34.0 million in Q1 2026, $266000.0 in Q4 2025, and -$277000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 65.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.35 Mn |
| Jun 30, 2026 | 65.35 Mn |
| Mar 31, 2026 | 34.02 Mn |
| Mar 31, 2026 | 34.02 Mn |
| Dec 31, 2025 | 266,000.00 |
| Dec 31, 2025 | 266,000.00 |
| Sep 30, 2025 | -277,000.00 |
| Sep 30, 2025 | -277,000.00 |
| Jun 30, 2025 | -67.55 Mn |
| Jun 30, 2025 | -67.55 Mn |
| Mar 31, 2025 | 65.18 Mn |
| Mar 31, 2025 | 65.18 Mn |
| Dec 31, 2024 | 19.99 Mn |
| Dec 31, 2024 | 19.99 Mn |
| Sep 30, 2024 | -46.33 Mn |
| Sep 30, 2024 | -46.33 Mn |
| Jun 30, 2024 | 8.96 Mn |
| Jun 30, 2024 | 8.96 Mn |
| Mar 31, 2024 | 40.22 Mn |
| Mar 31, 2024 | 40.22 Mn |